Risk factor
Good trading liquidity
Profitability factor
Very strong margins and returns
About
Anhui Anke Biotechnology (Group) Co., Ltd. is engaged in the research, manufacturing, and global distribution of pharmaceutical goods, serving both domestic Chinese and international markets. Its flagship offerings include Ansomone, a brand of recombinant human growth hormone administered via injection, and the Anterferon line, which comprises recombinant human interferon alpha 2b in various forms such as lyophilized powder, liquid, and prefilled syringes for injection, alongside creams, eye drops, and suppositories. The company also supplies an array of diagnostic kits, including those for detecting anti-sperm antibodies, performing semen leukocyte peroxidase staining, single-use semen processing, sperm hypo-osmotic staining, assessing sperm viability, analyzing sperm morphology, determining sperm acrosin levels, identifying sperm DNA fragmentation, and for leptin and immunohistochemical analyses. Furthermore, their product portfolio extends to adhesive bandages, liquid oral medications, various topical formulations (including creams and ointments), active pharmaceutical ingredients (APIs) derived from peptides, cosmetic and anti-aging treatments, and synthetic pharmaceutical compounds available as powders, dripping pills, and both tablets and capsules. Moreover, Anke Biotechnology offers genetic testing solutions, encompassing kits for autosomal, sex chromosome, and combined autosomal and sex chromosome analyses, along with complete paternity testing packages. They also develop biological immunotherapy treatments for tumors and provide specialized DNA testing services. Established in 2000, the firm's headquarters are situated in Hefei, China.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, r